EQRx has licensed two late-stage immuno-oncology agents from CStone Pharmaceuticals. The licensing agreement covers sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1).
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
